Eloïse Laouenan Presents the Results of HEMOTHEPP-CHU Brest-GETBO Prospective Study
Eloïse Laouenan, PhD student in Life and Health Sciences, INSERM, shared on LinkedIn:
”Thanks to the CNGOF and the Pari(s) Santé Femmes congress for this opportunity to present the results of the epidemiology of VTE in the HEMOTHEPP/CHU Brest/GETBO prospective multicenter cohort study (20,238 unselected pregnant women included at delivery, followed 3 months).
Upcoming publication…
– High incidence of postpartum VTE
– Under-prescription of thromboprophylaxis
– Half of VTEs after 7 days postpartum
– High incidence in women at intermediate risk, with or without thromboprophylaxis
VTE risk assessment +++
Perspective: MUM-VTE CHU Brest/GETBO equals multicenter randomized controlled trial (F-CRIN INNOVTE) to evaluate the efficacy and safety of postpartum thromboprophylaxis in women at intermediate risk.
Thanks to all the patients and investigators.
Personal thanks to my team at Service de gynécologie obstétrique et médecine de la reproduction – CHU Brest !!!
Thanks for the photo and support!”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving